Quarterly ResultApr 30, 2026, 07:12 AM
ACIU ACI-24 Triggers $12M Milestone; Lilly Morphomer Tau Deal Amended
AI Summary
AC Immune SA reported Q1 2026 financial and corporate updates, highlighting significant progress in its neurodegenerative disease pipeline. The company initiated the final cohort of its ACI-24 trial for Alzheimer's, triggering a $12 million milestone payment from Takeda, and amended its Morphomer Tau collaboration with Lilly, securing a CHF10 million upfront payment. AC Immune also advanced its NLRP3 inhibitor ACI-19764 into Phase 1 clinical development and expects multiple data readouts in 2026. The company's cash resources of CHF 74.8 million are projected to fund operations into Q4 2027, and its net loss improved to CHF 14.8 million in Q1 2026 from CHF 19.0 million in Q1 2025.
Key Highlights
- ACI-24 Phase 1b/2 ABATE trial initiated final cohort AD4, triggering $12M milestone from Takeda.
- Amended Morphomer Tau collaboration with Lilly includes CHF10M upfront payment and potential CHF1.7B milestones.
- Dosed first subjects in Phase 1 trial of brain-penetrant NLRP3 inhibitor ACI-19764.
- Cash resources of CHF 74.8M as of March 31, 2026, providing funding into Q4 2027.
- Q1 2026 net loss was CHF 14.8M, an improvement from CHF 19.0M in Q1 2025.
- Q1 2026 R&D expenses decreased to CHF 11.8M from CHF 15.9M in Q1 2025.
- Anticipates H2 2026 final data from Part 1 of ACI-7104 VacSYn Phase 2 trial.
- Anticipates Q2 2026 12-month interim results for ACI-24 AD3 cohort.
Price Impact
More from ACIU